Mangrove Partners Relmada Therapeutics, Inc. Transaction History

Mangrove Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $4.26 Million - $7.83 Million	-258,094 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $2.09 Million - $3.37 Million	125,000 Added 93.92%	258,094 $6.97 Million
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $441,432 - $699,304	-26,074 Reduced 16.38%	133,094 $3 Million
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $2.45 Million - $3.9 Million	112,192 Added 238.83%	159,168 $4.17 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $1.39 Million - $1.84 Million	46,976 New	46,976 $1.5 Million

13.5M

85.8K

42.8K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $100M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.